Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia
- PMID: 9446659
Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia
Abstract
The role of T lymphocytes in the control of chronic myeloid leukemia (CML) after bone marrow transplantations has been clearly shown. This effect closely correlates with graft-versus-host disease (GVHD). A specific graft-versus-leukemia (GVL) effect separate from GVHD has been postulated but has been difficult to show. One possible target for specific GVL activity is the bcr-abl fusion protein characteristic of CML. We have investigated the use of normal peptide-pulsed dendritic cells for the generation of cytotoxic, bcr-abl-specific T cells from normal donors. T cells (CD3+, CD8+, TCR alpha beta+, and NK receptor-negative) generated from a normal donor (HLA A24, B52, B59, Cw1) after stimulation with autologous dendritic cells, primed with a 16 mer peptide spanning the b3a2 breakpoint of bcr-abl, lysed CML cells from the peripheral blood of seven patients with CML with the b3a2 breakpoint. CML cells from four patients with only the b2a2 breakpoint were not lysed. Phytohemagglutinin (PHA) blasts derived from peripheral blood of patients with CML were not lysed, suggesting that cytotoxicity was not due to alloreactivity. Blocking experiments with anti-HLA-A,B,C indicated that cytotoxicity was dependent on recognition of major histocompatibility complex (MHC) class I molecules, although cytotoxicity was not MHC-restricted because not all patients shared HLA types with the T-cell donor. Specificity for bcr-abl and absence of alloreactivity was confirmed by the presence of lytic activity against autologous and allogeneic class I HLA-A matched monocytes pulsed with the 16 mer bcr-abl fusion peptide, but not against unpulsed monocytes or monocytes pulsed with other peptides. These results show that bcr-abl-specific T cells with marked cytotoxic activity against CML cells can be generated and amplified from normal donor peripheral blood. Recognition of HLA molecules is essential for cytotoxicity but strict HLA identity is not required.
Similar articles
-
Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients.Leukemia. 1999 Feb;13(2):166-74. doi: 10.1038/sj.leu.2401311. Leukemia. 1999. PMID: 10025889
-
HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.Blood. 2001 Sep 1;98(5):1498-505. doi: 10.1182/blood.v98.5.1498. Blood. 2001. PMID: 11520800
-
Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide.Blood. 1996 Nov 1;88(9):3522-7. Blood. 1996. PMID: 8896419
-
Chronic myeloid leukemia as an immunological target.Am J Hematol. 1997 Jan;54(1):61-7. doi: 10.1002/(sici)1096-8652(199701)54:1<61::aid-ajh9>3.0.co;2-2. Am J Hematol. 1997. PMID: 8980262 Review.
-
CML vaccines as a paradigm of the specific immunotherapy of cancer.Blood Rev. 2000 Jun;14(2):111-20. doi: 10.1054/blre.2000.0127. Blood Rev. 2000. PMID: 11012250 Review.
Cited by
-
Generation of V α13/β21+T cell specific target CML cells by TCR gene transfer.Oncotarget. 2016 Dec 20;7(51):84246-84257. doi: 10.18632/oncotarget.12441. Oncotarget. 2016. PMID: 27713165 Free PMC article.
-
Prevalence of the BCR/ABL fusion gene and T cell stimulation capacity of dendritic cells in chronic myelogenous leukemia.Am J Transl Res. 2023 Feb 15;15(2):967-981. eCollection 2023. Am J Transl Res. 2023. PMID: 36915720 Free PMC article.
-
Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells.Immunology. 2000 Feb;99(2):229-34. doi: 10.1046/j.1365-2567.2000.00952.x. Immunology. 2000. PMID: 10692041 Free PMC article.
-
Harnessing Dendritic Cells for Poly (D,L-lactide-co-glycolide) Microspheres (PLGA MS)-Mediated Anti-tumor Therapy.Front Immunol. 2019 Apr 5;10:707. doi: 10.3389/fimmu.2019.00707. eCollection 2019. Front Immunol. 2019. PMID: 31024545 Free PMC article. Review.
-
Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?Cancer Immunol Immunother. 2009 Sep;58(9):1489-99. doi: 10.1007/s00262-009-0675-x. Epub 2009 Mar 4. Cancer Immunol Immunother. 2009. PMID: 19259670 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous